ORY — ORYZON Genomics SA Share News
0.000.00%
Last trade - 00:00- €204.89m
- €196.06m
Brief: Oryzon To Execute Share Capital Increase For Up To 25 Mln Euros Through Accelerated Book Building
Brief: Oryzon Announces First Patient Dosed In Nci-Sponsored Phase I/Ii Clinical Trial Of Iadademstat Plus Immune Checkpoint Inhibitors In 1L Extensive Stage Small Cell Lung Cancer
Brief: Oryzon Says First Patient Dosed In Phase I/II Clinical Trial Of Iadademstat with Immune Checkpoint Inhibitors
Europe Research Roundup: EasyJet, Gym Group, Orsted
Brief: Oryzon Publishes Results Of Observational Clinical Study On PMS Patients
Brief: Oryzon Genomics FY Net Loss At 3.7 Mln Euros
Brief: Oryzon Announces Publication Of Final Phase IIa Results With Vafidemstat In Psychiatry
Brief: Oryzon Announces First Patient Dosed In Phase I Study Of Iadademstat In Myelodysplastic Syndrome
Brief: ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat
Brief: Oryzon Receives Russian Patent For Vafidemstat Until At Least 2040
Spanish stocks - Factors to watch on Nov 22
Brief: Oryzon Says Nice & Green Requests 1.3 Mln Euro Bond Conversion
Spanish stocks - Factors to watch on Oct. 25
Brief: Oryzon 9-Month Net Loss At 2.3 Mln Euros
Spanish stocks - Factors to watch on Oct 14
Brief: Oryzon Announces Formal Grant Of Key European Patent For Vafidemstat
Spanish stocks - Factors to watch on Oct 1
Brief: Oryzon Says FDA Supports Initiation Of Phase III Trial For Vafidemstat In Borderline Personality Disorder
Brief: Oryzon Says Nice & Green Requests Conversion Of Bonds For 540,000 Euros